Can concepts from CLL be applied to other liquid and solid tumors?
Safety analysis of the BCL-2 inhibitor venetoclax for CLL
Changes in research to overcome the problem of resistance to new CLL drugs
TGR-1202 in CLL and non-Hodgkin lymphoma
Why venetoclax is a promising new drug for CLL